A RANDOMIZED PHASE 3 STUDY COMPARING FIRST-LINE PEMETREXED PLUS CISPLATIN FOLLOWED BY GEFITINIB AS MAINTENANCE WITH GEFITINIB MONOTHERAPY IN EAST ASIAN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSQNSCLC)

被引：0
|
作者：
Yang, James C. [1 ]
Park, Keunchil [2 ]
Mok, Tony Shu Kam [3 ]
Kang, Jin Hyoung [4 ]
Srimuninnimit, Vichien [5 ]
Lin, Chia-Chi [1 ]
Kim, Dong-Wan [6 ]
Tsai, Chun-Ming [7 ]
Barraclough, Helen [8 ]
Altug, Sedat [9 ]
Orlando, Mauro [10 ]
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
[2] Samsung Med Ctr, Seoul, South Korea
[3] Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China
[4] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea
[5] Mahidol Univ, Div Med Oncol, Bangkok 10700, Thailand
[6] Seoul Natl Univ Hosp, Seoul, South Korea
[7] Taipei Vet Gen Hosp, Taipei, Taiwan
[8] Eli Lilly Australia, West Ryde, NSW, Australia
[9] Eli Lilly Instanbul, Istanbul, Turkey
[10] Eli Lilly Interamer Inc, Buenos Aires, DF, Argentina
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
EGFR; East-Asian patients; non-small cell lung cancer; pemetrexed;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO06.04
引用
收藏
页码：S288 / S288
页数：1
相关论文
共 50 条
  • [1] A randomized Phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non-small cell lung cancer (nSqNSCLC): Final survival results.
    Yang, James Chih-Hsin
    Srimuninnimit, Vichien
    Ahn, Myung-Ju
    Lin, Chia-Chi
    Kim, Sang-We
    Tsai, Chun-Ming
    Mok, Tony
    Orlando, Mauro
    Puri, Tarun
    Wang, Xin
    Park, Keunchil
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] A RANDOMISED PHASE 3 STUDY COMPARING FIRST-LINE PEMETREXED PLUS CISPLATIN FOLLOWED BY GEFITINIB AS MAINTENANCE WITH GEFITINIB MONOTHERAPY IN EAST ASIAN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
    Yang, J. C-H.
    Park, K.
    Mok, T.
    Kang, J. H.
    Srimuninnimit, V.
    Lin, C. -C.
    Kim, D. -W.
    Tsai, C. -M.
    Orlando, M.
    Nair, R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : E27 - E27
  • [3] First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
    Yang, James Chih-Hsin
    Kang, Jin Hyoung
    Mok, Tony
    Ahn, Myung-Ju
    Srimuninnimit, Vichien
    Lin, Chia-Chi
    Kim, Dong-Wan
    Tsai, Chun-Ming
    Barraclough, Helen
    Altug, Sedat
    Orlando, Mauro
    Park, Keunchil
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (13) : 2219 - 2230
  • [4] First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study
    Yang, James Chih-Hsin
    Srimuninnimit, Vichien
    Ahn, Myung-Ju
    Lin, Chia-Chi
    Kim, Sang-We
    Tsai, Chun-Ming
    Mok, Tony
    Orlando, Mauro
    Puri, Tarun
    Wang, Xin
    Park, Keunchil
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (03) : 370 - 379
  • [5] First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial
    Boye, Mark
    Wang, Xin
    Srimuninnimit, Vichien
    Kang, Jin Hyoung
    Tsai, Chun-Ming
    Orlando, Mauro
    Puri, Tarun
    Kim, Jon Seok
    Rajan, Narayan
    Yang, James Chih-Hsin
    [J]. CLINICAL LUNG CANCER, 2016, 17 (02) : 150 - 160
  • [6] Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial
    Kang, Jin Hyoung
    Ahn, Myung-Ju
    Kim, Dong-Wan
    Cho, Eun Kyung
    Kim, Joo-Hang
    Shin, Sang Won
    Wang, Xin
    Kim, Jong Seok
    Orlando, Mauro
    Park, Keunchil
    [J]. CANCER RESEARCH AND TREATMENT, 2016, 48 (02): : 458 - 464
  • [7] Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer
    Ahn, Myung-Ju
    Yang, James Chih-Hsin
    Liang, Jun
    Kang, Jin-Hyoung
    Xiu, Qingyu
    Chen, Yuh-Min
    Blair, Julie Michelle
    Peng, Guangbin
    Linn, Carlos
    Orlando, Mauro
    [J]. LUNG CANCER, 2012, 77 (02) : 346 - 352
  • [8] Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    Brown, T.
    Boland, A.
    Bagust, A.
    Oyee, J.
    Hockenhull, J.
    Dundar, Y.
    Dickson, R.
    Ramani, V. S.
    Proudlove, C.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 71 - 79
  • [9] Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer
    Schmid-Bindert, Gerald
    Gebbia, Vittorio
    Mayer, Frank
    Arriola, Edurne
    Marquez-Medina, Diego
    Syrigos, Kostas
    Biesma, Bonne
    Leschinger, Monika Iris
    Frimodt-Moller, Bente
    Ripoche, Veronique
    Myrand, Scott P.
    Nguyen, Tuan S.
    Hozak, Rebecca R.
    Zimmermann, Annamaria
    Visseren-Grul, Carla
    Schuette, Wolfgang
    [J]. LUNG CANCER, 2013, 81 (03) : 428 - 434
  • [10] First-line cisplatin plus pemetrexed therapy for selected patients with advanced nonsquamous non-small cell lung cancer.
    Nakashima, Kazuhisa
    Murakami, Haruyasu
    Imai, Hisao
    Ono, Akira
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Endo, Masahiro
    Takahashi, Toshiaki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345